Abstract

BackgroundDrug-coated balloon (DCB) is a new technology that has emerged in recent years and has been proven to be effective and safe in the treatment of in-stent restenosis. The purpose of this article is to observe the safety and effectiveness of drug-coated balloons in patients with acute myocardial infarction.MethodWe selected 80 patients admitted to the hospital for STEMI from January 2018 to December 2019. The subjects were randomly divided into a Yinyi (Liaoning) Biotech Bingo Drug Coated Balloon treatment group (balloon group, n = 38) and a drug-eluting stent (DES) treatment group (stent group, n = 42). Patients were followed up to understand the incidence of major adverse cardiovascular events (MACE) at 1 month, 6 months and 1 year after surgery. Coronary angiography was rechecked 1 year after surgery to understand the late lumen loss (LLL) in the two groups.ResultDuring the one-year follow-up, the LLL of the target lesion in the balloon group was -0.12±0.46 mm, while the target lesion in the stent group was 0.14±0.37 mm ( P <0.05). Within 1 year, the incidence of MACE in the balloon group was 11%, while the incidence of MACE in the stent group was 12%. There was no significant difference between the two groups.ConclusionWhen PCI is used for STEMI, only DCB therapy is safe and effective, and has shown good clinical effects during a one-year follow-up period.

Highlights

  • Drug-coated balloon (DCB) is a new technology that has emerged in recent years and has been proven to be effective and safe in the treatment of in-stent restenosis

  • When Percutaneous coronary intervention (PCI) is used for STEMI, only DCB therapy is safe and effective, and has shown good clinical effects during a one-year follow-up period

  • Participants: STEMI patients who were hospitalized in the Cardiovascular Department of our hospital from January 2018 to December 2019 and received emergency PCI treatment

Read more

Summary

Introduction

Drug-coated balloon (DCB) is a new technology that has emerged in recent years and has been proven to be effective and safe in the treatment of in-stent restenosis. The purpose of this article is to observe the safety and effectiveness of drug-coated balloons in patients with acute myocardial infarction. Percutaneous coronary intervention (PCI) for acute ST-segment elevation myocardial infarction (STEM I) can minimize the size of myocardial infarction and restore the blood perfusion of ischemic myocardial tissue. PCI usually includes coronary stent implantation and percutaneous transluminal coronary angioplasty (PTCA). Stent implantation is the preferred treatment for patients with acute myocardial infarction. The second-generation drug-eluting stent (DES) is the main method of interventional treatment of coronary artery disease [4].

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.